Financial Performance - As of December 31, 2022, the company has an accumulated deficit of $262.5 million[166] - The company anticipates continued significant operating losses for the foreseeable future[166] - The company has incurred substantial operating losses since inception and expects to continue incurring losses[185] Product Development - The company has not generated any product sales from any product candidates to date[162] - The company has not received approval for the sale of any product candidate in any market[162] - The confirmed objective response rate (ORR) for cosibelimab in a Phase 1 clinical trial for metastatic CSCC was 47.4% based on independent central review of 78 patients[159] - The interim results for cosibelimab in a Phase 1 clinical trial for locally advanced CSCC showed an ORR of 54.8% based on independent central review of 31 patients[164] Clinical Trials - The CONTERNO study for cosibelimab in combination with chemotherapy is expected to be wound down and closed by the end of Q1 2023 due to disruptions caused by the conflict in Ukraine[160] Market Value - The aggregate market value of the voting stock held by non-affiliates as of June 30, 2022, was $71.4 million based on a closing stock price of $10.30[171] Collaborations - The company has entered into collaboration agreements with TGTX to develop and commercialize certain assets in hematological malignancies[161]
Checkpoint Therapeutics(CKPT) - 2022 Q4 - Annual Report